Long non-coding RNA MALAT1 in hematological malignancies and its clinical applications
10.1097/CM9.0000000000003090
- VernacularTitle:Long non-coding RNA MALAT1 in hematological malignancies and its clinical applications
- Author:
Chunlan ZHANG
1
;
Yun QIN
;
Yu WU
;
Heng XU
;
Yang SHU
Author Information
1. Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
- Keywords:
Long non-coding RNA;
MALAT1;
Hematological malignancies;
Tumorigenesis;
Metastasis;
Drug resistance;
Prognostic biomarker
- From:
Chinese Medical Journal
2024;137(10):1151-1159
- CountryChina
- Language:Chinese
-
Abstract:
Metastasis-associated lung adenocarcinoma transcript 1 ( MALAT1) is a well-established oncogenic long non-coding RNA, the higher expression of which is strongly correlated with cancer events such as tumorigenesis, progression, metastasis, drug resistance, and treatment outcome in solid cancers. Recently, a series of studies has highlighted its potential role in hematological malignancies in terms of these events. Similar to solid cancers, MALAT1 can regulate various target genes via sponging and epigenetic mechanisms, but the miRNAs sponged by MALAT1 differ from those identified in solid cancers. In this review, we systematically describe the role and underlying mechanisms of MALAT1 in multiple types of hematological malignancies, including regulation of cell proliferation, metastasis, stress response, and glycolysis. Clinically, MALAT1 expression is related to poor treatment outcome and drug resistance, therefore exhibiting potential prognostic value in multiple myeloma, lymphoma, and leukemia. Finally, we discuss the evaluation of MALAT1 as a novel therapeutic target against cancer in preclinical studies.
